Effect of direct-acting antiviral (DAA) drugs on HCV epidemiology among patients in public hospitals in southern Hessen, Germany.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028846

Enrollment

10000

Registered

2022-07-20

Start date

2022-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients' blood is tested for hepatitis C virus (HCV) antibodies. If the result is positive, the next step is to check for HCV RNA to detect an active infection.

Interventions

Group 1: Patients presenting for elective surgery or emergency care to a public hospital in southern Hessen are tested for HCV antibodies, using an ELISA test. The positive samples are then tested for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Consenting patients over the age of 18 presenting for elective surgery or emergency care to a public hospital in southern Hessen, Germany

Exclusion criteria

Exclusion criteria: Patients under 18 years of age, patients with a known HCV infection

Design outcomes

Primary

Measure	Time frame
Prevalence of hepatitis C antibodies in patients presenting for elective surgery or emergency care i to a public hospital in southern Hessen, Germany.	—

Secondary

Measure	Time frame
Effect of therapy (direct-acting antiviral drugs) on the prevalence of infection with HCV.	—

Countries

Germany

Contacts

Public ContactKatharina Grikscheit

Institut für Medizinische Virologie, Universitätsklinikum Frankfurt am Main

katharina.grikscheit@kgu.de+4969630186101

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026